Trastuzumab mafodotin
Highest phase reached
Phase 1
Drug type
Antibody drug conjugate
- Listing at source
- Listed
- Highest phase reached
- Phase 1
- Drug type
- Antibody drug conjugate
- Drug name
- Trastuzumab mafodotin
- fs 1502
- Fs-1502
- FS-1502
- iks 014
- IKS-014
- iks014
- lcb 14
- Lcb-14
- lcb14 0110
- Lcb14-0110
- trastuzumab mafodotin
- Trastuzumab mafodotin
- Trastuzumab mafodotin [WHO-DD]
- trastuzumab mafodotin who dd
- trastuzumab monomethyl auristatin f
- Trastuzumab monomethyl auristatin F
- ChEMBL ID
- CHEMBL6068604
- FDA ingredient codes (UNII)
- FWA9E3VB3K
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -dotin; -mab; -mab
Open Targets indications
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 3
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (3)
- FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
- IKS014 in Advanced Solid Tumors That Express HER2
- Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.
In development for (1)
- Breast cancer Phase 3